0001479290-20-000067.txt : 20200515
0001479290-20-000067.hdr.sgml : 20200515
20200515183952
ACCESSION NUMBER: 0001479290-20-000067
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200514
FILED AS OF DATE: 20200515
DATE AS OF CHANGE: 20200515
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: GARDNER PHYLLIS
CENTRAL INDEX KEY: 0001238646
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36297
FILM NUMBER: 20887283
MAIL ADDRESS:
STREET 1: 618 MIRADA AVENUE
CITY: STANFORD
STATE: CA
ZIP: 94305
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Revance Therapeutics, Inc.
CENTRAL INDEX KEY: 0001479290
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 770551645
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 7555 GATEWAY BLVD.
CITY: NEWARK
STATE: CA
ZIP: 94560
BUSINESS PHONE: 510-742-3400
MAIL ADDRESS:
STREET 1: 7555 GATEWAY BLVD.
CITY: NEWARK
STATE: CA
ZIP: 94560
4
1
wf-form4_158958237463980.xml
FORM 4
X0306
4
2020-05-14
0
0001479290
Revance Therapeutics, Inc.
RVNC
0001238646
GARDNER PHYLLIS
C/O REVANCE THERAPEUTICS, INC
7555 GATEWAY BOULEVARD
NEWARK
CA
94560
1
0
0
0
Common Stock
2020-05-14
4
A
0
6000
0
A
16500
D
Stock Option (Right to buy)
19.4
2020-05-14
4
A
0
12000
0
A
2030-05-13
Common Stock
12000.0
12000
D
Represents an annual restricted stock award (the "RSA") granted pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Policy (the "Compensation Policy"). The shares underlying the RSA shall vest on May 14, 2021, the one year anniversary from the grant date, subject to Dr. Gardner's Continuous Service (as defined the Issuer's 2014 Equity Incentive Plan (the "Plan")) through such vesting date.
The shares subject to the stock option shall vest on May 14, 2021, the one year anniversary from the grant date, subject to Dr. Gardner's Continuous Service (as defined in the Plan) through such vesting date. The stock option represents an annual grant pursuant to the Compensation Policy.
/s/ Gordon Ho, Attorney-in-Fact
2020-05-15